595 related articles for article (PubMed ID: 12021250)
41. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.
Polyzos SA; Perakakis N; Mantzoros CS
Metabolism; 2019 Jul; 96():66-82. PubMed ID: 31071311
[TBL] [Abstract][Full Text] [Related]
42. Review article: hepatic steatosis and insulin resistance.
Lonardo A; Lombardini S; Ricchi M; Scaglioni F; Loria P
Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():64-70. PubMed ID: 16225477
[TBL] [Abstract][Full Text] [Related]
43. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.
Javor ED; Cochran EK; Musso C; Young JR; Depaoli AM; Gorden P
Diabetes; 2005 Jul; 54(7):1994-2002. PubMed ID: 15983199
[TBL] [Abstract][Full Text] [Related]
44. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
[TBL] [Abstract][Full Text] [Related]
45. Pathway-selective insulin resistance and metabolic disease: the importance of nutrient flux.
Otero YF; Stafford JM; McGuinness OP
J Biol Chem; 2014 Jul; 289(30):20462-9. PubMed ID: 24907277
[TBL] [Abstract][Full Text] [Related]
46. Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo.
Fishman S; Muzumdar RH; Atzmon G; Ma X; Yang X; Einstein FH; Barzilai N
FASEB J; 2007 Jan; 21(1):53-60. PubMed ID: 17099068
[TBL] [Abstract][Full Text] [Related]
47. Dysfunction of lipid metabolism in lipodystrophic Seipin-deficient mice.
Wang M; Gao M; Liao J; Han Y; Wang Y; Liu G
Biochem Biophys Res Commun; 2015 May; 461(2):206-10. PubMed ID: 25866184
[TBL] [Abstract][Full Text] [Related]
48. [Recognize rare diseases by the adipose tissue : Lipodystrophy-actually simple but nevertheless often overlooked].
Wabitsch M; V Schnurbein J
Internist (Berl); 2020 Oct; 61(10):1063-1075. PubMed ID: 32930809
[TBL] [Abstract][Full Text] [Related]
49. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
Takahashi N; Qi Y; Patel HR; Ahima RS
J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
[TBL] [Abstract][Full Text] [Related]
50. Lipodystrophies: adipose tissue disorders with severe metabolic implications.
Cortés VA; Fernández-Galilea M
J Physiol Biochem; 2015 Sep; 71(3):471-8. PubMed ID: 25833179
[TBL] [Abstract][Full Text] [Related]
51. Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report.
Pedicelli S; de Palma L; Pelosini C; Cappa M
Ital J Pediatr; 2020 Oct; 46(1):158. PubMed ID: 33099310
[TBL] [Abstract][Full Text] [Related]
52. Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice.
Riddle TM; Fichtenbaum CJ; Hui DY
J Acquir Immune Defic Syndr; 2003 Aug; 33(5):564-70. PubMed ID: 12902799
[TBL] [Abstract][Full Text] [Related]
53. Lipodystrophy Syndromes.
Hussain I; Garg A
Endocrinol Metab Clin North Am; 2016 Dec; 45(4):783-797. PubMed ID: 27823605
[TBL] [Abstract][Full Text] [Related]
54. Effect of leptin infusion on insulin sensitivity and lipid metabolism in diet-induced lipodystrophy model mice.
Nagao K; Inoue N; Ujino Y; Higa K; Shirouchi B; Wang YM; Yanagita T
Lipids Health Dis; 2008 Mar; 7():8. PubMed ID: 18348717
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance.
Roden M
Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):335-48. PubMed ID: 16932311
[TBL] [Abstract][Full Text] [Related]
56. A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities.
Ozgen Saydam B; Sonmez M; Simsir IY; Erturk MS; Kulaksizoglu M; Arkan T; Hekimsoy Z; Cavdar U; Akinci G; Demir T; Altay CT; Mihci E; Secil M; Akinci B
Endocr Res; 2019; 44(1-2):46-54. PubMed ID: 30182761
[TBL] [Abstract][Full Text] [Related]
57. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
[TBL] [Abstract][Full Text] [Related]
58. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.
Lebastchi J; Ajluni N; Neidert A; Oral EA
J Clin Endocrinol Metab; 2015 Nov; 100(11):3967-70. PubMed ID: 26390101
[TBL] [Abstract][Full Text] [Related]
59. Triglyceride-induced diabetes mellitus in congenital generalized lipodystrophy.
Montenegro RM; Montenegro AP; Fernandes MI; de Moraes RR; Elias J; Gouveia LM; Muglia VF; Foss MC; Moreira AC; Martinelli CE
J Pediatr Endocrinol Metab; 2002 Apr; 15(4):441-7. PubMed ID: 12008692
[TBL] [Abstract][Full Text] [Related]
60. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes.
Perry RJ; Samuel VT; Petersen KF; Shulman GI
Nature; 2014 Jun; 510(7503):84-91. PubMed ID: 24899308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
